Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Rilan Bai(Jilin University), Jiuwei Cui(Jilin University)
Cited by 473
Related Papers
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|504
Mechanisms of Cancer Resistance to Immunotherapy
|Frontiers in Oncology|2020|346
Increased expression of claudin-17 promotes a malignant phenotype in hepatocyte via Tyk2/Stat3 signaling and is associated with poor prognosis in patients with hepatocellular carcinoma
|Diagnostic Pathology|2018|31
Distinct biological effects of low-dose radiation on normal and cancerous human lung cells are mediated by ATM signaling
|Oncotarget|2016|27
Expert consensus on treatment for stage III non‐small cell lung cancer
|Medicine Advances|2023|18